

human subjects as it poses no compromise on human health upon its use. This will aid in determining whether previous research carried out was specie-specific or perhaps drug-specific. In addition, it is worthy afterwards to further investigate the category of drugs affected by glucosamine metabolic inhibition of liver enzymes as proposed by previous research as species interact differently with drugs and it should be assessed on each drug individually hopefully leading to structure related prediction of drugs to be affected by glucosamine as first pass effect inhibitor. In addition to the need to confirm in future design of experiments that the drugs metabolized through Cytochrome P-450 pathway may lead to increased bioavailability when given concomitantly with glucosamine.